Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

32.28
+1.023.25%
Post-market: 32.500.2250+0.70%19:30 EDT
Volume:1.29M
Turnover:41.54M
Market Cap:2.31B
PE:-5.47
High:32.97
Open:31.42
Low:31.03
Close:31.26
52wk High:56.05
52wk Low:21.15
Shares:71.71M
Float Shares:62.80M
Volume Ratio:0.52
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8984
EPS(LYR):-4.6644
ROE:-91.75%
ROA:-46.76%
PB:5.68
PE(LYR):-6.92

Loading ...

Vera Therapeutics Grants Inducement Stock Options and RSUs to Six New Hires

Reuters
·
Mar 07

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Vera Therapeutics appoints Hite to Board of Directors

TIPRANKS
·
Mar 05

Vera Therapeutics Appoints Christopher Hite to Board of Directors

GlobeNewswire
·
Mar 05

Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02

Bank of America Securities Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Mar 02

Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright

TIPRANKS
·
Mar 02

Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)

Simply Wall St.
·
Feb 28

Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating

TIPRANKS
·
Feb 28

Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating

MT Newswires Live
·
Feb 27

Guggenheim Keeps Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Feb 27

Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate

Benzinga Earnings
·
Feb 27

Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity

TIPRANKS
·
Feb 27

Vera Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 27

Vera Therapeutics' 2025 net loss wider than expectations

Reuters
·
Feb 26

Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%

Reuters
·
Feb 26

BRIEF-Vera Therapeutics FY EPS USD -4.66 Vs. IBES Estimate USD -4.55

Reuters
·
Feb 26

Vera Therapeutics FY Operating Expenses USD 315.473 Million

THOMSON REUTERS
·
Feb 26

Vera Therapeutics FY EPS USD -4.66 VS. Ibes Estimate USD -4.55

THOMSON REUTERS
·
Feb 26

Vera Therapeutics Inc - Atacicept Commercial Launch Expected Mid-2026

THOMSON REUTERS
·
Feb 26